Cyprotex Appoints Dr Rob Elsby as Leader of Drug Transporter Team
News Mar 18, 2015
Dr Elsby is a recognised expert in the drug transporter field, as exemplified by his numerous publications including co-authoring an International Transporter Consortium (ITC) whitepaper. These publications span such areas as the validation of in vitro transporter assays, predicting clinical DDI exposure changes for statins, and the role that transporter pharmacogenetics play in mediating ethnic differences in statin exposure. Dr Elsby’s role at Cyprotex will involve leading the strategic direction of Cyprotex’s transporter based assays both in terms of new research and its client-based services.
Prior to joining Cyprotex, Dr Elsby worked within a DMPK (Drug Metabolism and Pharmacokinetics) function at AstraZeneca where, over a period of 11 years, he helped develop the internal drug transporter scientific capability both practically and strategically. During this time his expert knowledge and technical interpretation of drug transporter science was routinely used towards the provision of drug disposition and clinical DDI (drug-drug interaction) risk understanding to global discovery and development project teams.
Dr Elsby will be presenting new research performed at Cyprotex in the field of transporters at the AAPS/ITC Joint Workshop on Drug Transporters in Baltimore, USA in April 2015. The research focuses on the impact of inhibitor pre-incubation time on uptake transporter interactions in vitro.
On joining Cyprotex, Dr Elsby said “I am very excited to be joining a leading scientific team that can utilise its specialist services/expertise to fully integrate in vitro ADME, transporter and toxicity data with PBPK (physiologically based pharmacokinetic) modelling approaches towards obtaining a more holistic prediction of a molecule’s safety profile in humans.”
Dr Anthony Baxter, Cyprotex’s Chief Executive Officer said, “We are delighted to welcome Dr Elsby to our scientific team. Rob’s experience in the extrapolation of in vitro drug transporter interactions to the clinical situation will be vital in assisting our customers in understanding the relevance of the data generated. Through expansion of its transporter capabilities, Cyprotex can now offer the full range of in vitro assays for regulatory DDI (drug-drug interaction) packages.”
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Chili Pepper Derived Anti-Obesity Drug Shows Promise in Animal TrialsNews
A novel drug based on capsaicin, the compound that gives chili peppers their spicy burn, caused long term weight loss and improved metabolic health in mice eating a high fat diet.READ MORE
5th edition of the International Conference Clinical Oncology and Molecular Diagnostics
Jun 17 - Jun 18, 2019